Supportive Care and Targeted Treatments for D-2-HGA

Managing D-2-hydroxyglutaric aciduria (D-2-HGA) requires a highly individualized approach. Because there is no single “cure” for the condition, the focus of medical care is to manage symptoms, support development, and protect the heart and brain from the effects of chemical buildup ^[1].

Standard Supportive Care

Most children with D-2-HGA benefit from a “multidisciplinary” team—a group of specialists who work together to address different aspects of the disease ^[1].

• Neurological Support: Pediatric neurologists manage seizures and monitor brain health ^[2]. Seizure management usually involves standard anti-seizure medications tailored to the child’s specific type of epilepsy ^[1].
• Cardiac Monitoring: Especially in Type 2, regular check-ups with a pediatric cardiologist are essential. This often includes echocardiograms (heart ultrasounds) to monitor for dilated cardiomyopathy (a weakened heart muscle) and ECGs to check for heart rhythm issues ^[3][4].
• Therapeutic Services: Early intervention with physical, occupational, and speech therapy is critical for supporting children with developmental delays or low muscle tone (hypotonia) ^[1][3].
• Emergency Planning: It is standard practice to have a written “Emergency Protocol” from your metabolic specialist to ensure that local hospitals understand your child’s rare needs during an acute illness ^[3].

A Critical Note on Diet

In many metabolic disorders, the first line of treatment is a highly restrictive diet. However, it is vital to understand that D-2-HGA is not the same as other “look-alike” conditions.

Warning: There is no established routine lysine- or protein-restricted diet for confirmed D-2-HGA. Families should not start a GA1 diet based only on a nonspecific total 2-hydroxyglutarate result, nor should they stop a nutrition plan individually prescribed for a coexisting problem ^[5][6]. Because the biochemical “clog” is different in D-2-HGA, unguided restrictions do not help lower D-2HG levels and can actually cause nutritional deficiencies that harm a growing child ^[5][1]. Any dietary restrictions or changes must be directed by a metabolic dietitian.

Emerging and Investigational Therapies

For children with Type 2 D-2-HGA (caused by IDH2 gene mutations), researchers are exploring a new approach called “targeted therapy.”

Enasidenib (AG-221)

Enasidenib is an investigational, off-label therapy originally developed to treat a type of adult leukemia. There is no established pediatric dose or proven disease-modifying benefit for D-2-HGA, and families must not start, stop, or alter dosing independently.

Current evidence for its use in D-2-HGA is limited entirely to uncontrolled case reports.

• Reported Observations: In a few reported cases, Enasidenib was associated with drops in D-2HG levels, along with anecdotal observations of reduced seizures and improved heart function ^[3][4]. However, a falling biomarker does not automatically establish clinical effectiveness, and apparent developmental gains may have multiple explanations.

Side Effects and Monitoring

Because use is investigational, the long-term pediatric safety is unknown, and any consideration must occur through an expert team or ethically monitored trial. Known side effects include:

• Liver and Muscle Enzymes: Case reports have described elevations in ALT (a liver enzyme) and CK (a muscle enzyme). These represent case-specific observations, not a standard monitoring plan ^[3].
• Severe Complications: In oncology use, Enasidenib carries a serious risk of differentiation syndrome, a potentially fatal complication, though its relevance in D-2-HGA is uncertain.
• Hyperbilirubinemia: A common side effect is an increase in bilirubin, which can cause a yellow tint to the skin or eyes (jaundice) ^[7]. In reported pediatric cases, this was often “asymptomatic,” meaning it didn’t make the child feel sick ^[4].
• Drug Interactions: Enasidenib can interact with many other medications. Your doctor must review all of your child’s prescriptions to avoid harmful interactions ^[8].

Because this treatment is still considered experimental for D-2-HGA, it should only be managed by a specialized metabolic team capable of frequent laboratory and cardiac monitoring ^[3].